An Evaluation of “Drug Ineffective” Postmarketing Reports in Drug Safety Surveillance View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-02-23

AUTHORS

Takashi Misu, Cindy M. Kortepeter, Monica A. Muñoz, Eileen Wu, Gerald J. Dal Pan

ABSTRACT

INTRODUCTION: The most commonly reported adverse event, based on frequency of Medical Dictionary for Regulatory Activities (MedDRA) preferred terms (PTs), in the US FDA Adverse Event Reporting System (FAERS) database is "drug ineffective" (DI). This study aimed to describe the DI reports and provide data to support recommendations on how to best evaluate these reports. METHODS: We characterized all FAERS reports coded with the MedDRA PT "drug ineffective" received between 1 September 2012 and 31 August 2016 using all other FAERS reports as a comparator. Additionally, we conducted a manual evaluation to identify informative data elements in the report narratives. RESULTS: During the study period, 247,513 (6.4% of all FAERS reports) DI reports were entered in FAERS. Compared with non-DI reports, DI reports were more likely to be reported by consumers (69.8 vs. 48.1%) and less likely to report a serious outcome (26.2 vs. 56.3%). Most DI reports (88%) were from the USA. Manual evaluation of 552 sample US reports identified 43 reports (7.8%) deemed "useful"; a higher proportion of "useful" reports provided a batch or lot number (39.5 vs. 17.2%) and were coded with additional PTs beyond "drug ineffective" (83.7 vs. 59.2%), the most frequent of which were "product quality issue" (23.3%) and "product substitution issue" (18.6%). CONCLUSIONS: DI was the most frequently reported adverse event in the FAERS database; however, the yield from these reports in terms of usefulness from a pharmacovigilance perspective was low. Efficient strategies are needed to identify which DI reports are more likely to contain useful information. More... »

PAGES

91-99

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40801-018-0131-3

DOI

http://dx.doi.org/10.1007/s40801-018-0131-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1101189323

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29476420


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Office of Safety II, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.490702.8", 
          "name": [
            "Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD USA", 
            "Office of Safety II, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Misu", 
        "givenName": "Takashi", 
        "id": "sg:person.013622142523.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013622142523.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD USA", 
          "id": "http://www.grid.ac/institutes/grid.483500.a", 
          "name": [
            "Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kortepeter", 
        "givenName": "Cindy M.", 
        "id": "sg:person.01154140753.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154140753.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD USA", 
          "id": "http://www.grid.ac/institutes/grid.483500.a", 
          "name": [
            "Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mu\u00f1oz", 
        "givenName": "Monica A.", 
        "id": "sg:person.01025111121.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025111121.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD USA", 
          "id": "http://www.grid.ac/institutes/grid.483500.a", 
          "name": [
            "Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wu", 
        "givenName": "Eileen", 
        "id": "sg:person.01276704641.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276704641.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD USA", 
          "id": "http://www.grid.ac/institutes/grid.483500.a", 
          "name": [
            "Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dal Pan", 
        "givenName": "Gerald J.", 
        "id": "sg:person.0623331723.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623331723.56"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2018-02-23", 
    "datePublishedReg": "2018-02-23", 
    "description": "INTRODUCTION: The most commonly reported adverse event, based on frequency of Medical Dictionary for Regulatory Activities (MedDRA) preferred terms (PTs), in the US FDA Adverse Event Reporting System (FAERS) database is \"drug ineffective\" (DI). This study aimed to describe the DI reports and provide data to support recommendations on how to best evaluate these reports.\nMETHODS: We characterized all FAERS reports coded with the MedDRA PT \"drug ineffective\" received between 1 September 2012 and 31 August 2016 using all other FAERS reports as a comparator. Additionally, we conducted a manual evaluation to identify informative data elements in the report narratives.\nRESULTS: During the study period, 247,513 (6.4% of all FAERS reports) DI reports were entered in FAERS. Compared with non-DI reports, DI reports were more likely to be reported by consumers (69.8 vs. 48.1%) and less likely to report a serious outcome (26.2 vs. 56.3%). Most DI reports (88%) were from the USA. Manual evaluation of 552 sample US reports identified 43 reports (7.8%) deemed \"useful\"; a higher proportion of \"useful\" reports provided a batch or lot number (39.5 vs. 17.2%) and were coded with additional PTs beyond \"drug ineffective\" (83.7 vs. 59.2%), the most frequent of which were \"product quality issue\" (23.3%) and \"product substitution issue\" (18.6%).\nCONCLUSIONS: DI was the most frequently reported adverse event in the FAERS database; however, the yield from these reports in terms of usefulness from a pharmacovigilance perspective was low. Efficient strategies are needed to identify which DI reports are more likely to contain useful information.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40801-018-0131-3", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1051855", 
        "issn": [
          "2199-1154", 
          "2198-9788"
        ], 
        "name": "Drugs - Real World Outcomes", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "5"
      }
    ], 
    "keywords": [
      "adverse events", 
      "FAERS reports", 
      "FDA Adverse Event Reporting System (FAERS) database", 
      "Adverse Event Reporting System database", 
      "US FDA Adverse Event Reporting System (FAERS) database", 
      "Reporting System database", 
      "postmarketing reports", 
      "drug safety surveillance", 
      "serious outcomes", 
      "FAERS database", 
      "US reports", 
      "study period", 
      "safety surveillance", 
      "pharmacovigilance perspective", 
      "Medical Dictionary", 
      "System database", 
      "report", 
      "drugs", 
      "higher proportion", 
      "additional Pt", 
      "regulatory activity", 
      "FAERS", 
      "ineffective", 
      "evaluation", 
      "outcomes", 
      "data elements", 
      "surveillance", 
      "database", 
      "manual evaluation", 
      "events", 
      "proportion", 
      "substitution issues", 
      "terms of usefulness", 
      "period", 
      "recommendations", 
      "activity", 
      "useful information", 
      "comparator", 
      "study", 
      "usefulness", 
      "report narratives", 
      "frequency", 
      "data", 
      "strategies", 
      "number", 
      "product quality issues", 
      "efficient strategy", 
      "di", 
      "USA", 
      "information", 
      "issues", 
      "terms", 
      "Pt", 
      "perspective", 
      "consumers", 
      "quality issues", 
      "batch", 
      "elements", 
      "narratives", 
      "yield", 
      "dictionary", 
      "Event Reporting System (FAERS) database", 
      "DI reports", 
      "MedDRA PT", 
      "drug ineffective", 
      "informative data elements", 
      "non-DI reports", 
      "Most DI", 
      "sample US reports", 
      "product substitution issue"
    ], 
    "name": "An Evaluation of \u201cDrug Ineffective\u201d Postmarketing Reports in Drug Safety Surveillance", 
    "pagination": "91-99", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1101189323"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40801-018-0131-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29476420"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40801-018-0131-3", 
      "https://app.dimensions.ai/details/publication/pub.1101189323"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:42", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_782.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40801-018-0131-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0131-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0131-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0131-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0131-3'


 

This table displays all metadata directly associated to this object as RDF triples.

164 TRIPLES      21 PREDICATES      96 URIs      88 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40801-018-0131-3 schema:about anzsrc-for:11
2 anzsrc-for:1117
3 schema:author N5718f89dfb9a43dca12cc0ec17b9f89e
4 schema:datePublished 2018-02-23
5 schema:datePublishedReg 2018-02-23
6 schema:description INTRODUCTION: The most commonly reported adverse event, based on frequency of Medical Dictionary for Regulatory Activities (MedDRA) preferred terms (PTs), in the US FDA Adverse Event Reporting System (FAERS) database is "drug ineffective" (DI). This study aimed to describe the DI reports and provide data to support recommendations on how to best evaluate these reports. METHODS: We characterized all FAERS reports coded with the MedDRA PT "drug ineffective" received between 1 September 2012 and 31 August 2016 using all other FAERS reports as a comparator. Additionally, we conducted a manual evaluation to identify informative data elements in the report narratives. RESULTS: During the study period, 247,513 (6.4% of all FAERS reports) DI reports were entered in FAERS. Compared with non-DI reports, DI reports were more likely to be reported by consumers (69.8 vs. 48.1%) and less likely to report a serious outcome (26.2 vs. 56.3%). Most DI reports (88%) were from the USA. Manual evaluation of 552 sample US reports identified 43 reports (7.8%) deemed "useful"; a higher proportion of "useful" reports provided a batch or lot number (39.5 vs. 17.2%) and were coded with additional PTs beyond "drug ineffective" (83.7 vs. 59.2%), the most frequent of which were "product quality issue" (23.3%) and "product substitution issue" (18.6%). CONCLUSIONS: DI was the most frequently reported adverse event in the FAERS database; however, the yield from these reports in terms of usefulness from a pharmacovigilance perspective was low. Efficient strategies are needed to identify which DI reports are more likely to contain useful information.
7 schema:genre article
8 schema:inLanguage en
9 schema:isAccessibleForFree true
10 schema:isPartOf N854a65d4dd174d97956606c94acd22db
11 Nda1f14d84f5e47a2a6666fcd7140f7a3
12 sg:journal.1051855
13 schema:keywords Adverse Event Reporting System database
14 DI reports
15 Event Reporting System (FAERS) database
16 FAERS
17 FAERS database
18 FAERS reports
19 FDA Adverse Event Reporting System (FAERS) database
20 MedDRA PT
21 Medical Dictionary
22 Most DI
23 Pt
24 Reporting System database
25 System database
26 US FDA Adverse Event Reporting System (FAERS) database
27 US reports
28 USA
29 activity
30 additional Pt
31 adverse events
32 batch
33 comparator
34 consumers
35 data
36 data elements
37 database
38 di
39 dictionary
40 drug ineffective
41 drug safety surveillance
42 drugs
43 efficient strategy
44 elements
45 evaluation
46 events
47 frequency
48 higher proportion
49 ineffective
50 information
51 informative data elements
52 issues
53 manual evaluation
54 narratives
55 non-DI reports
56 number
57 outcomes
58 period
59 perspective
60 pharmacovigilance perspective
61 postmarketing reports
62 product quality issues
63 product substitution issue
64 proportion
65 quality issues
66 recommendations
67 regulatory activity
68 report
69 report narratives
70 safety surveillance
71 sample US reports
72 serious outcomes
73 strategies
74 study
75 study period
76 substitution issues
77 surveillance
78 terms
79 terms of usefulness
80 useful information
81 usefulness
82 yield
83 schema:name An Evaluation of “Drug Ineffective” Postmarketing Reports in Drug Safety Surveillance
84 schema:pagination 91-99
85 schema:productId N1d09bfb110ca4af0bdfe9b46126c2b0f
86 Nd50ce56a543747dbade24406d268dd36
87 Nfa2822e4ab0046269d1fc544d8bffb40
88 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101189323
89 https://doi.org/10.1007/s40801-018-0131-3
90 schema:sdDatePublished 2021-12-01T19:42
91 schema:sdLicense https://scigraph.springernature.com/explorer/license/
92 schema:sdPublisher Nec91f3b1229f45e69742ab79f6b5f6b0
93 schema:url https://doi.org/10.1007/s40801-018-0131-3
94 sgo:license sg:explorer/license/
95 sgo:sdDataset articles
96 rdf:type schema:ScholarlyArticle
97 N1d09bfb110ca4af0bdfe9b46126c2b0f schema:name doi
98 schema:value 10.1007/s40801-018-0131-3
99 rdf:type schema:PropertyValue
100 N5718f89dfb9a43dca12cc0ec17b9f89e rdf:first sg:person.013622142523.08
101 rdf:rest Nb2a08d8b3c974d4ab75d2c9e7e703627
102 N854a65d4dd174d97956606c94acd22db schema:volumeNumber 5
103 rdf:type schema:PublicationVolume
104 Na7e991e47cb344eaab34e8080549bcbc rdf:first sg:person.01276704641.35
105 rdf:rest Ne4f80cee45244ef39614eaa79669475b
106 Nb2a08d8b3c974d4ab75d2c9e7e703627 rdf:first sg:person.01154140753.84
107 rdf:rest Nf2a7878feddd46e589c777238fdff3a8
108 Nd50ce56a543747dbade24406d268dd36 schema:name dimensions_id
109 schema:value pub.1101189323
110 rdf:type schema:PropertyValue
111 Nda1f14d84f5e47a2a6666fcd7140f7a3 schema:issueNumber 2
112 rdf:type schema:PublicationIssue
113 Ne4f80cee45244ef39614eaa79669475b rdf:first sg:person.0623331723.56
114 rdf:rest rdf:nil
115 Nec91f3b1229f45e69742ab79f6b5f6b0 schema:name Springer Nature - SN SciGraph project
116 rdf:type schema:Organization
117 Nf2a7878feddd46e589c777238fdff3a8 rdf:first sg:person.01025111121.33
118 rdf:rest Na7e991e47cb344eaab34e8080549bcbc
119 Nfa2822e4ab0046269d1fc544d8bffb40 schema:name pubmed_id
120 schema:value 29476420
121 rdf:type schema:PropertyValue
122 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
123 schema:name Medical and Health Sciences
124 rdf:type schema:DefinedTerm
125 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
126 schema:name Public Health and Health Services
127 rdf:type schema:DefinedTerm
128 sg:journal.1051855 schema:issn 2198-9788
129 2199-1154
130 schema:name Drugs - Real World Outcomes
131 schema:publisher Springer Nature
132 rdf:type schema:Periodical
133 sg:person.01025111121.33 schema:affiliation grid-institutes:grid.483500.a
134 schema:familyName Muñoz
135 schema:givenName Monica A.
136 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025111121.33
137 rdf:type schema:Person
138 sg:person.01154140753.84 schema:affiliation grid-institutes:grid.483500.a
139 schema:familyName Kortepeter
140 schema:givenName Cindy M.
141 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154140753.84
142 rdf:type schema:Person
143 sg:person.01276704641.35 schema:affiliation grid-institutes:grid.483500.a
144 schema:familyName Wu
145 schema:givenName Eileen
146 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276704641.35
147 rdf:type schema:Person
148 sg:person.013622142523.08 schema:affiliation grid-institutes:grid.490702.8
149 schema:familyName Misu
150 schema:givenName Takashi
151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013622142523.08
152 rdf:type schema:Person
153 sg:person.0623331723.56 schema:affiliation grid-institutes:grid.483500.a
154 schema:familyName Dal Pan
155 schema:givenName Gerald J.
156 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623331723.56
157 rdf:type schema:Person
158 grid-institutes:grid.483500.a schema:alternateName Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD USA
159 schema:name Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD USA
160 rdf:type schema:Organization
161 grid-institutes:grid.490702.8 schema:alternateName Office of Safety II, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan
162 schema:name Office of Safety II, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan
163 Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD USA
164 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...